期刊文献+

血清肿瘤相关物质检测在骨肿瘤诊断中的应用 被引量:2

Serum tumor associated material detection in the diagnosis of bone tumors
下载PDF
导出
摘要 目的:了解血清肿瘤相关物质(serum tumor associated material,TAM)在骨肿瘤患者中的表达情况,及其表达在骨原发恶性肿瘤及骨转移瘤中的意义。方法:对2012-2014年间郑州大学第一附属医院骨科200例瘤患者临床TAM检验值数据采集分组并进行统计学分析从而得出结论。结果:良性肿瘤组(A组)TAM表达平均值(86.36±6.873)U/ml,阳性率8%;恶性肿瘤组(B组)平均值(108.28±21.603)U/ml,阳性率80%;转移瘤组(C组)平均值(111.04±16.744)U/ml,阳性率84%;非肿瘤组(D组)平均值(87.5±6.438)U/ml,阳性率6%。TAM平均值A组与D组之间、B组与C组之间无显著差异,A、D两组与B、C两组之间两两差异显著。TAM检测值阳性率A、D两组与B、C两组的差异均具有统计学意义,A组与D组、B组与C组的差异不具有统计学意义。结论:TAM是一敏感性高,广谱、价廉、检查方便的肿瘤相关物质,在骨原发恶性肿瘤及骨转移瘤中明显高于骨良性肿瘤及良性病变的检测值,阳性率高达80%以上。 Objective:To study the serum tumor associated material (TAM) on the expression of bone tumors crowd, and its expression in primary malignant tumor of bone and bone metastases. Methods: To collect the data of the First Affiliated Hospital of Zhengzhou University from 2012 to 2014 for 200 patients with TAM. Results : In benign tumor group (group A), the TAM expression measured average was (86.36 ±6. 873)U/ml, positive rate 8%, malignant tumor group ( group B) the measured average ( 108.28 ± 21. 603 ) U/ml, positive rate 80%, metastases group ( group C) measured average ( 111.04 ± 16. 744 ) U/ml, positive rate 84%, non - tumor group ( group D) measured average (87.5±6. 438) U/ml, positive rate 6%. TAM had no significant difference and was not statistically significant between group A and group D, so was group B and group C. Group B/C and group A/D had remarkable difference. TAM had statistically significant differences in group A/D and group B/C. Conclusion:TAM is a tumor related substances with high sensitivity, broad spectrum ,low price and easy to check. The positive rate in the primary malignant tumor of bone and bone metastases was obvious higher than that of benign tumor,which was as high as 80% or above.
出处 《现代肿瘤医学》 CAS 2016年第1期129-132,共4页 Journal of Modern Oncology
基金 河南省医学科技攻关计划普通项目(编号:201403023)
关键词 血清肿瘤相关物质 骨肿瘤 骨转移瘤 serum tumor associated material, bone tumors, bone metastases
  • 相关文献

参考文献7

二级参考文献32

  • 1吴健民.对肿瘤标志物的再认识[J].中华检验医学杂志,2005,28(1):11-13. 被引量:116
  • 2段永强,王梅林,汪晓龙.TSGF测定在肺癌中的临床应用[J].临床肿瘤学杂志,2004,9(6):644-644. 被引量:8
  • 3胜利,安利峰,史霖,王军阳,范桂香,袁育康.结肠癌患者外周血DcR3与CEA联合测定的临床价值[J].西安交通大学学报(医学版),2007,28(2):205-207. 被引量:7
  • 4Gold Pretman SD. Demomnstration of tumor - specific antigens in hu- man colonic carcinoma by immunological tolerance and absorption tech- niques[J]. J Exp Med, 1965,121:439.
  • 5吴恒兴.中国医学百科全书[M].上海:科学技术出版社,1983:63.
  • 6中华医学会检验医学分会肿瘤标志物专家委员会.肿瘤标志物检测临床应用的基本原则(讨论稿)[J].中华检验医学杂志,2004,:27-27.
  • 7王健 吉强 殷建华 等.AFP实验室检测40年[A]..肿瘤标志专题讨论会论文集[C].,2002.27-35.
  • 8Pritzker KH. Cancer biomarkers : easier said than done. Clin Chem, 2002,48: 1147- 1150.
  • 9Fleisher M, Dnistrian AM, Sturgeon CM, et al. Practice guidelines and recommendations for use tumor markers in the clinic. Washington DC: AACC Press,2002.20-25
  • 10Lichtenstein AV, Potapova GI. Genetic defects as tumor markers. Molecular Biol, 2003,37:159-169.

共引文献137

同被引文献15

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部